Neogen’s third quarter results showed progress in both its Food and Animal Safety segments, but the market reaction was negative. Management attributed the quarter’s performance to improved commercial execution, targeted customer engagement, and operational discipline. CEO Mikhael Nassif highlighted “tangible signs that the changes underway across Neogen are taking hold,” particularly with strengthened inventory planning and cross-functional collaboration. However, the company acknowledged that the timing of certain customer orders provided a temporary lift, suggesting the need for sustained improvement in core execution.
Is now the time to buy NEOG? Find out in our full research report (it’s free for active Edge members).
Neogen (NEOG) Q3 CY2026 Highlights:
- Revenue: $222.8 million vs analyst estimates of $208.3 million (6.5% year-on-year growth, 7% beat)
- Adjusted EPS: $0.08 vs analyst estimates of $0.05 (50% beat)
- Adjusted EBITDA: $41.6 million vs analyst estimates of $36.67 million (18.7% margin, 13.5% beat)
- The company slightly lifted its revenue guidance for the full year to $887.5 million at the midpoint from $882.5 million
- EBITDA guidance for the full year is $182 million at the midpoint, above analyst estimates of $179.3 million
- Operating Margin: -0.8%, up from -7.7% in the same quarter last year
- Market Capitalization: $2.55 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Neogen’s Q3 Earnings Call
- Brandon Vazquez (William Blair) asked about the flat full-year EBITDA margin guidance despite year-over-year expansion. CFO Bryan Riggsbee explained that incremental investments and duplicative costs related to transformation will weigh on margins in the first half, with improvements expected later in the year.
- Brandon Vazquez (William Blair) questioned whether Neogen is currently gaining market share. CEO Mikhael Nassif and Chief Commercial Officer Joe Freels said the new sales model and focus on global strategic accounts are driving competitive wins, with early evidence of share gains.
- Subhalaxmi Nambi (Guggenheim Securities) requested growth expectations for indicator testing and sanitation segments. Freels said targeted commercial focus and new KPI reviews should sustain high-single-digit growth rates in these lines.
- Subhalaxmi Nambi (Guggenheim Securities) asked about inventory management during the Petrifilm transition. Nassif outlined the revamped approach, emphasizing safety stock, supplier management, and disciplined SKU sequencing as key safeguards.
- Bob Labick (CJS Securities) inquired about the financial impact and timeline for duplicative costs from the Petrifilm transition. Riggsbee replied that these costs will peak and then decline as the transition completes, with margin expansion expected to materialize in subsequent years.
Catalysts in Upcoming Quarters
Going forward, the StockStory team will monitor (1) the successful execution of the Petrifilm manufacturing transition and associated cost reduction, (2) the pace and impact of new product innovation and partnerships, and (3) progress on operational efficiency initiatives that support margin expansion. The upcoming closure of the genomics divestiture and its effect on the balance sheet will also be key metrics for assessing Neogen’s execution against its strategy.
Neogen currently trades at $11.51, down from $11.99 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
